Showing 1 - 10 of 560
Persistent link: https://www.econbiz.de/10009616664
Persistent link: https://www.econbiz.de/10008873538
Health care costs represent a nearly 18% of U.S. gross domestic product and 20% of government spending. While there is detailed information on where these health care dollars are spent, there is much less evidence on how this spending affects health. The research in Measuring and Modeling Health...
Persistent link: https://www.econbiz.de/10014479897
Persistent link: https://www.econbiz.de/10011294610
The emergence of targeted therapies in oncology has enormous potential to improve care for individual patients and specific subpopulations. A consequence of these advances is the segmentation of oncology into numerous sub-types, often with small patient populations. In this research we document...
Persistent link: https://www.econbiz.de/10013096654
Precision medicines inherently fragment treatment populations, generating small-population markets, creating high-priced "niche busters" rather than broadly prescribed "blockbusters". It is plausible to expect that small markets will attract limited entry in which a small number of...
Persistent link: https://www.econbiz.de/10012943199
The economics of stratified medicine depend critically on setting the cut-off score of the companion diagnostic (CDx). This action integrates scientific, clinical, ethical and commercial considerations, and simultaneously determines the value of the stratified medicine to developers, providers,...
Persistent link: https://www.econbiz.de/10013021484
Persistent link: https://www.econbiz.de/10012020069
Persistent link: https://www.econbiz.de/10011772984
Precision medicines inherently fragment treatment populations, generating small-population markets, creating high-priced "niche busters" rather than broadly prescribed "blockbusters". It is plausible to expect that small markets will attract limited entry in which a small number of...
Persistent link: https://www.econbiz.de/10012453693